Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer

Edith A. Perez, Francois J. Geoffroy, Shauna Hillman, Elizabeth A. Johnson, Gist H. Farr, Henry D. Tazelarr, Alan K. Hatfield, James E. Krook, James A. Maillard, Ralph Levitt, Randolph S. Marks

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Background: This study evaluated the activity and tolerance for the combination of oral etoposide and paclitaxel as first-line therapy for patients with extensive SCLC. Methods: A total of 57 patients were enrolled in this study. A cycle of chemotherapy consisted of oral etoposide administered as 50 mg BID on days 1 through 10 and paclitaxel administered as 150 mg/m2 IV (3 h infusion) along with the first dose of etoposide on day 10. Patients were assessed for response to therapy (regression, stable disease, progression), survival, time to disease progression, and toxicity. Results/conclusions: Fifty-five patients were evaluable for efficacy parameters. Among the 55 patients, there were six with complete regression of disease, 18 with partial regression, 11 with regression, five with stable disease, and 15 with progressive disease, yielding an overall response rate of 63.6% (95% confidence interval, 50.0-76.0%). The 6-month and 1-year progression-free survival rates were 48.2 and 18.9%, respectively. The median time to disease progression was 5.8 months. The overall survival rates were 67.3% at 6 months and 41.8% at 1 year. The combination of oral etoposide and paclitaxel demonstrated significant efficacy as first-line therapy for extensive SCLC, with an overall response rate of 63.6% for 55 evaluable patients. In addition, the treatment was well tolerated with no unexpected toxicities.

Original languageEnglish (US)
Pages (from-to)347-353
Number of pages7
JournalLung Cancer
Volume44
Issue number3
DOIs
StatePublished - Jun 1 2004

Keywords

  • Etoposide
  • Oral chemotherapy
  • Paclitaxel
  • Small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Perez, E. A., Geoffroy, F. J., Hillman, S., Johnson, E. A., Farr, G. H., Tazelarr, H. D., Hatfield, A. K., Krook, J. E., Maillard, J. A., Levitt, R., & Marks, R. S. (2004). Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer. Lung Cancer, 44(3), 347-353. https://doi.org/10.1016/j.lungcan.2003.12.002